MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Pliant Therapeutics Inc

Closed

1.55 -5.49

Overview

Share price change

24h

Current

Min

1.55

Max

1.5899999999999999

Key metrics

By Trading Economics

Income

13M

-43M

Profit margin

-2,190.837

Employees

171

EBITDA

17M

-42M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+70.7% upside

Dividends

By Dow Jones

Next Earnings

6 lis 2025

Market Stats

By TradingEconomics

Market Cap

-13M

91M

Previous open

7.04

Previous close

1.55

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Pliant Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 paź 2025, 18:13 UTC

Major Market Movers

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

17 paź 2025, 17:05 UTC

Major Market Movers

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

18 paź 2025, 13:30 UTC

Acquisitions, Mergers, Takeovers

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18 paź 2025, 13:30 UTC

Acquisitions, Mergers, Takeovers

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18 paź 2025, 13:30 UTC

Acquisitions, Mergers, Takeovers

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18 paź 2025, 13:30 UTC

Acquisitions, Mergers, Takeovers

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18 paź 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

18 paź 2025, 07:00 UTC

Earnings

A Growing Nimby Movement Could Upend the Data Center Boom -- Barrons.com

17 paź 2025, 23:25 UTC

Acquisitions, Mergers, Takeovers

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 paź 2025, 22:15 UTC

Market Talk

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 paź 2025, 21:15 UTC

Market Talk

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

17 paź 2025, 21:07 UTC

Market Talk

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

17 paź 2025, 21:07 UTC

Market Talk

Global Equities Roundup: Market Talk

17 paź 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 paź 2025, 20:34 UTC

Market Talk

Deere Is Reaching the End of Its Downcycle -- Market Talk

17 paź 2025, 20:27 UTC

Market Talk

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

17 paź 2025, 19:46 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

17 paź 2025, 19:45 UTC

Market Talk

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

17 paź 2025, 18:45 UTC

Market Talk

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

17 paź 2025, 17:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 paź 2025, 17:51 UTC

Market Talk

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

17 paź 2025, 17:44 UTC

Market Talk

EQT Seen With Long-Term Growth Opportunities -- Market Talk

17 paź 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

17 paź 2025, 16:20 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

17 paź 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 paź 2025, 16:14 UTC

Market Talk

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

17 paź 2025, 16:04 UTC

Market Talk

Home Improvement Demand Is Starting to Pick Up -- Market Talk

17 paź 2025, 15:58 UTC

Market Talk

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

17 paź 2025, 15:56 UTC

Earnings

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17 paź 2025, 15:43 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer Comparison

Price change

Pliant Therapeutics Inc Forecast

Price Target

By TipRanks

70.7% upside

12 Months Forecast

Average 2.68 USD  70.7%

High 4 USD

Low 1.7 USD

Based on 7 Wall Street analysts offering 12 month price targets forPliant Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

7 ratings

1

Buy

5

Hold

1

Sell

Technical Score

By Trading Central

1.43 / 1.6Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
help-icon Live chat